Danaher Corp. May Be the Smartest Bet in Biotech Right Now

Biotech funding has been in a down cycle for roughly the past four years. Higher interest rates, tighter capital markets, and a collapse in funding after 2021 forced a lot of early stage biotech companies to cut spending, delay trials, or shut down entirely. But that trend is starting to shift.Early 2026 data show biopharma spending is stabilizing and beginning to recover, with contract research firms and suppliers reporting improving demand as funding conditions loosen and deal activity picks back up. Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool